Tatyana Feldman

机构：Hackensack University Medical Center, Hackensack Meridian Health · ORCID：0000-0002-4458-2896

发表论文 370 篇 · 总被引 12040 次 · h-index 42

代表论文

• Camidanlumab tesirine for relapsed or refractory classic Hodgkin lymphoma: a phase 2 study (2025 · Blood Advances · 被引 8)
• Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years’ follow-up (2025 · Blood Cancer Journal · 被引 5)
• Efficacy and safety of epcoritamab in relapsed or refractory large B-cell lymphoma: 3-year update from the EPCORE NHL-1 trial (2026 · Annals of Hematology · 被引 4)
• Association of PET4 response with outcomes of BV-CHP vs CHOP in the ECHELON-2 trial in CD30+ peripheral T-cell lymphoma (2025 · Blood Advances · 被引 2)
• Prognosis and treatment of plasmablastic lymphoma in the United States: a multicenter retrospective study (2026 · Blood Cancer Journal · 被引 1)
• Final results of a phase 1 trial with soquelitinib (SQL), a selective interleukin-2-inducible T cell kinase (ITK) inhibitor for treatment of relapsed/refractory (R/R) T cell lymphomas (TCL) (2025 · Blood · 被引 1)